Comparison of Liraglutide Versus Placebo in Weight Loss Maintenance in Obese Subjects: SCALE - Maintenance

NCT00781937 · Completed

Last updated 2026-05-28

This clinical trial tested whether the medication liraglutide helps people who are obese maintain weight loss compared to a placebo.

Status Completed The study has finished.

Phase Phase 3 Confirms effectiveness in a large group before approval.

Type Interventional (clinical trial)

Design Randomized, double-blind treatment study

Participants 422 people

Who can join Ages 18+ · all sexes

Timeline Started 2008-10 · est. completion 2010-09

Where 37 sites · Canada, United States

What this study is testing ClinicalTrials.gov NCT00781937 ↗

Description as written by the study sponsor.

This trial is conducted in North America. The aim of this clinical trial is to evaluate the potential of liraglutide to maintain long term weight loss in obese non-diabetic subjects, as well as in overweight subjects who have medical problems such as hypertension (high blood pressure) or dyslipidaemia (an abnormal amount of lipids in the blood). Trial has following trial periods: A 12-week run-in period (from week -12 to week 0) followed by a 56-week main trial period (weeks 0-56) and a 12-week follow-up period (weeks 56-68).

Treatments tested

liraglutide Drug

Liraglutide 3.0 mg per day administered in a 6.0 mg/mL, 3 mL FlexPen® for subcutaneous (under the skin) injection, once daily
placebo Drug

Liraglutide placebo 3 mL FlexPen® for subcutaneous (under the skin) injection, once daily

Main thing measured	Mean Percentage Change in Fasting Body Weight From Baseline
Sponsor	Novo Nordisk A/S
Conditions studied	Metabolism and Nutrition Disorder, Obesity
GLP-1 drugs	liraglutide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT00781937 ↗